Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Proteasome02:18

The Proteasome

9.3K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
9.3K
The Proteasome01:13

The Proteasome

1.2K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.2K
The Proteasome02:18

The Proteasome

3.8K
3.8K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.6K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.6K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

2.3K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
2.3K
Hematopoiesis01:21

Hematopoiesis

7.3K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
7.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Primary Myelofibrosis (PMF)-The German ONKOPEDIA Guideline 2025.

International journal of cancer·2026
Same author

The German ONKOPEDIA Guideline for Myelofibrosis in 2025-Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology (DGHO).

International journal of cancer·2026
Same author

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

Blood advances·2026
Same author

Type I interferon-activated NK cells control polycythemia vera in vivo.

Blood·2026
Same author

Value of functional iron parameters in diagnostic re-assessment of MPN: refinement of iron-deficiency markers by zinc protoporphyrin (ZPP).

Annals of hematology·2026
Same author

Novel de novo dominant <i>PSMB10</i> variants in three patients with immune deficiency and liver disease.

Journal of human immunity·2026

Related Experiment Video

Updated: Oct 30, 2025

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.5K

Immunoproteasome Function in Normal and Malignant Hematopoiesis.

Nuria Tubío-Santamaría1, Frédéric Ebstein2, Florian H Heidel1,3

  • 1Innere Medicine C, Universitätsmedizin Greifswald, 17475 Greifswald, Germany.

Cells
|July 2, 2021
PubMed
Summary

Targeting the immunoproteasome, a key part of protein regulation, offers a promising new strategy for treating blood cancers. This approach may overcome limitations of current proteasome inhibitors in hematologic malignancies.

Keywords:
hematologic malignancieshematopoiesisimmunoproteasome (iP)proteasome inhibitors (PIs)ubiquitin–proteasome system (UPS)

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.1K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

884

Related Experiment Videos

Last Updated: Oct 30, 2025

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.5K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.1K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

884

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • The ubiquitin-proteasome system (UPS) is crucial for protein homeostasis in hematopoietic cells.
  • Dysregulation of the UPS is implicated in the development of hematologic malignancies.
  • Current proteasome inhibitors are effective but face challenges like side effects and resistance.

Purpose of the Study:

  • To review the function and inhibition of the immunoproteasome in hematopoietic cells and cancers.
  • To explore immunoproteasome inhibitors as a potential therapeutic strategy for hematologic malignancies.

Main Methods:

  • Literature review of studies on immunoproteasome function.
  • Analysis of pre-clinical and clinical data on immunoproteasome inhibitors in hematologic cancers.

Main Results:

  • Immunoproteasome inhibitors show potential for treating hematologic malignancies.
  • These inhibitors may offer an alternative to non-selective proteasome inhibitors, potentially reducing side effects and overcoming resistance.
  • Early clinical trials for multiple myeloma show promising results.

Conclusions:

  • The immunoproteasome is a viable therapeutic target for hematologic cancers.
  • Further development of immunoproteasome inhibitors is warranted for treating blood cancers and related conditions.